Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22017691 | 0.70 | GRM4 (0.44) | GRM4CMA1 | |
| SCHEMBL22017689 | 0.64 | ADORA3 (0.45) | — | |
| SCHEMBL9534299 | 0.63 | ADORA3 (0.49) | GRM4 | |
| SCHEMBL22016877 | 0.61 | ADORA3 (0.41) | CMA1 | |
| SCHEMBL22016876 | 0.61 | AAK1 (0.40) | CMA1 | |
| SCHEMBL22016873 | 0.59 | AAK1 (0.39) | CMA1 | |
| SCHEMBL13322657 | 0.58 | MAPK14 (0.40) | GRM4 | |
| SCHEMBL13322656 | 0.58 | HPD (0.42) | GRM4 | |
| SCHEMBL22016240 | 0.55 | GRM4 (0.43) | GRM4CMA1 | |
| SCHEMBL23471345 | 0.55 | KAT2B (0.36) | GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | GRM4 3533/4885CMA1 146/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | GRM4 3533/4885CMA1 146/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | GRM4 3533/4885CMA1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.